Medexus Pharmaceuticals Inc (OTCPK:MEDXF)

Q1 2027 Medexus Pharmaceuticals Inc Earnings Call Transcript

Aug 11, 2026 / 12:00 PM GMT

Release Date Price: $3.79 (+6.46%)

Transcript

Key Points

Positve

Medexus Pharmaceuticals Inc (MEDXF) reported a strong first quarter with total net revenue increasing to $28.6 million from $24.6 million in the prior year, and adjusted EBITDA rising to $4.7 million from $3.4 million.
Graphopex delivered its strongest quarter to date, generating $4.9 million in product-level net revenue, with underlying patient demand growing 20% sequentially and 118% year-over-year.
Commercial adoption of Graphopex is progressing well, with 75 healthcare institutions having ordered the product and 54 placing repeat orders, indicating strong market acceptance.
The company maintains its long-term guidance for Graphopex to achieve annual product-level net revenue of $100 to $175 million within five years, supported by strong pricing and broad adoption.
Medexus Pharmaceuticals Inc (MEDXF) signed agreements for exclusive Canadian rights to commercialize 171 cell therapy, a strategic fit with its existing trio sulfan product, expanding its presence in the HSCT space.
The company's net debt to adjusted EBITDA ratio improved to a healthy 1.18 times, providing financial flexibility for future business development opportunities.

Negative

Cash used by operating activities was $0.7 million in Q1 2027, a decrease of $4.6 million compared to cash provided by operating activities in the prior year, primarily due to the settlement of year-end payables and working capital timing.
Gross margin decreased to 55.6% from 56.0% year-over-year, and adjusted gross margin fell to 63.8% from 65.5%, partly due to a one-time positive impact of royalty revenue in the prior year quarter.
The company faces potential tariff impacts, with a 15% EU-US tariff applying to Rasuvo and potentially to Graphopex, which could affect future margins, though currently deemed not material.
Rasuvo sales have been negatively impacted by genericization, losing about two-thirds of its unit volume, and while the rate of decline has slowed, market share continues to slowly erode.
The company's growth trajectory for Graphopex faces seasonality risks, with the summer months historically being challenging, though July 2026 was reported as the second-best month ever.
The regulatory path for 171 cell therapy in Canada is uncertain, with no guarantee of an expedited review, and the company is still awaiting a meeting with Health Canada.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

MDP.TO - Medexus Pharmaceuticals Inc
Q1 2027 Medexus Pharmaceuticals Inc Earnings Call
Aug 11, 2026 / 12:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Greetings.

Welcome to the Medexus Pharmaceuticals first quarter 2027 conference call.

At this time, all participants are in a listen-only mode.

A question-and-answer session will follow the formal presentation.

If anyone should require operator assistance during the conference.

Please press 0 on your telephone keypad.

Please note this conference is being recorded.

I will now turn the conference over to your host, Victoria Rutherford.

Investor relations, you may begin.

To the Pharmaceuticals first fiscal quarter 2027's earnings call.

On the call this morning are Ken Don Tremont, Chief Executive Officer, and Brendan Bushman,

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.